Compare FLNG & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNG | CSTL |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | Bermuda | United States |
| Employees | N/A | 823 |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 940.8M |
| IPO Year | N/A | 2019 |
| Metric | FLNG | CSTL |
|---|---|---|
| Price | $26.48 | $32.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $23.00 | ★ $46.67 |
| AVG Volume (30 Days) | 348.1K | ★ 424.7K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 11.35% | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $351,034,000.00 | $343,530,000.00 |
| Revenue This Year | N/A | $2.88 |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $14.53 | ★ N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $19.46 | $14.59 |
| 52 Week High | $27.67 | $44.28 |
| Indicator | FLNG | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 26.17 |
| Support Level | $25.88 | $31.64 |
| Resistance Level | $26.71 | $40.88 |
| Average True Range (ATR) | 0.58 | 1.96 |
| MACD | -0.05 | -1.09 |
| Stochastic Oscillator | 54.20 | 5.89 |
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.